943541-20-6

Basic information

• Product Name: 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine
• Synonyms: 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine
• CAS NO: 943541-20-6
• Molecular Formula: C₈H₇ClN₄
• Molecular Weight: 194.62
• Mol File: 943541-20-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine(943541-20-6)
• EPA Substance Registry System: 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine(943541-20-6)

Safety Data

• Hazardous Substances Data: 943541-20-6(Hazardous Substances Data)

Usage

General Description

The chemical 3-Chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine, also known as T-705, is a compound that belongs to the class of pyridazine compounds. It is known for its antiviral and antitumor properties and has been studied for its potential use in treating a variety of diseases, including influenza, Ebola virus, and SARS-CoV-2. T-705 works by inhibiting the replication of viral RNA, and it has shown promise in several preclinical studies. However, further research is needed to fully understand its potential applications and any potential side effects.

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 761446-44-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 135034-10-5 3-chloro-6-iodopyridazine 
• 1440965-04-7 3-chloro-6-(1-trityl-1H-pyrazol-4-yl)pyridazine 
• 1211519-08-2 3-chloro-6-(1H-pyrazol-4-yl)pyridazine 
• 75-26-3 isopropyl bromide 
• 74-88-4 methyl iodide 
• 847818-55-7 (1-methyl-1H-pyrazol-4-yl)boronic acid 
• 60-34-4 methylhydrazine 
• 1121-79-5 3-chloro-6-methylpyridazine 

Downstream Products

• 943540-75-8 JNJ-38877605 
• 1201929-62-5 3-[3-(5-bromopyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-18-8 6-(1-methyl-1H-pyrazol-4-yl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1,2,4-triazolo[4,3-b]pyridazine 
• 1201929-66-9 3-{[3-(5-bromopyrimidin-2-yl)phenyl]difluoromethyl}-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201929-80-7 6-(1-methyl-1H-pyrazol-4-yl)-3-[3-(5-morpholin-4-yl-pyrimidin-2-yl)benzyl]-1,2,4-triazolo[4,3-b]pyridazine 
• 1201929-84-1 3-(difluoro-{3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]-phenyl}methyl)-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201929-98-7 3-[difluoro-(3-pyrimidin-2-ylphenyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-24-6 3-{difluoro-[3-(5-iodopyrimidin-2-yl)phenyl]methyl}-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]-pyridazine 
• 1201930-21-3 3-{difluoro-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl}-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-23-5 3-[3-(5-iodopyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201929-82-9 3-{3-[5-(4-methylpiperazin-1-yl)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-17-7 3-(3-bromobenzyl)-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo-[4,3-b]pyridazine 
• 1201930-20-2 3-[(3-bromophenyl)difluoromethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1100598-42-2 2-[3-(5-bromo-pyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one 

Relevant articles and documents

Preparation method and intermediate of pyrazole compound

The invention discloses a preparation method and an intermediate of a pyrazole compound. The invention specifically discloses a preparation method of a compound B. The preparation method provided by the invention has one or more advantages as follows: the operation is simple, the yield is relatively high, the cost is low, and the method is suitable for industrial production.

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.

HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.